Clinico-microbiological profile and treatment outcomes in patients with isoniazid 1 monoresistant tuberculosis in South India 2

3

Venkata Prasanna M¹., Muthuraj R²., Vimal Raj R¹., Govindarajan S³, Pajanivel R^{*1}

4 5 6

1 Department of Respiratory Medicine, MGMCRI, Puducherry, 607402, INDIA.

- 2 Intermediate Reference Laboratory, Puducherry, 7
- 3.State Tuberculosis unit Officer, Puducherry 8
- 9

ABSTRACT 10

11

Isoniazid (INH) is an important first-line medication for the treatment of tuberculosis. 12 13 The impact that tuberculosis drug resistance has on treatment outcomes is a topic that is receiving a lot of attention these days because of the rising incidence of INH-14 15 resistant cases. Study involves a single group of patients who have been diagnosed with Isoniazid monoresistant tuberculosis. Treatment history and demographic data 16 of the patients were obtained after informed consent. The mutation patterns of 17 isoniazid were observed after multiplex PCR and Line Probe Assay (LPA). A total of 18 101 patient (M,F) records at the IRL, Puducherry were analyzed. The predominant 19 gene responsible for TB was KATG (67.3%). The KATG Mut1 was a prime mutation 20 observed in the present study population (58.41%). Study showed positive association 21 with males (74%), occupation as coolie (88%), diabetes as comorbidity (33%), 22 pulmonary tuberculosis as the TB site (98.01%), history of previous ATT intake in 43 23 patients (42.6%), katG mutation (67.3%), katG Mut 1 was the prime mutation 24 (58.4%). The cure rate was high in *INH high concentration resistance* patients which 25 statistically significant (p=0.0167). INH monoresistance mutations seen in 26 was 64.3% of the patients with katG, compared to inhA (34.65%). Similar to katG 27 28 mutations, inhA mutations also have MUT1 as their most frequent gene pattern. There is a significant association between males, diabetes, smoking and alcohol addictions 29 were associated with high risk of developing high dose INH monoresistance (katG). 30 High prevalence of recurrent tuberculosis was seen in high dose INH monoresistance 31 32 tuberculosis. Patients who are microbiologically confirmed pulmonary tuberculosis and diabetes with rifampicin sensitive status needs to be checked for LPA for 33 isoniazid sensitivity status to prevent treatment failure and relapse. It is crucial to 34 understand the gene pattern in each of these patients since these mutations are closely 35 36 associated to high or low-degree resistance to INH

37 **Keywords:** INH-resistant, LPA, ATT, katG, inhA, Ttuberculosis NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38

INTRODUCTION 39

40

One of the leading causes of death in developing and underdeveloped 41 42 Countries is Ttuberculosis (TB), which is caused by the bacteria Mycobacterium tuberculosis (MTB). According to the most recent statistics provided by the World 43 Health Organization (WHO), there were 6.4 million newly diagnosed cases of 44 Tuberculosis in the year 2021, a drop in incidence attributed to under reporting due 45 to covid 19 pandemic [1] although TB most frequently affects the lungs, it is also 46 47 capable of affecting other areas of the body. The incidence of TB is higher in India and claims the lives of over half a million people [2]. Today, India has the highest 48 number of cases of MTR-TB in the world and is responsible for one-fourth of the 49 worldwide burden of the disease and has much lower success rates [3]. There is 50 evidence that tuberculosis is gradually decreasing, the worldwide emergence and 51 52 spread of Multi Drug Resistance (MDR) have become a major obstacle [4]. The impact of Tuberculosis drug resistance and treatment outcomes has been a cause of 53 concern in the past few years because of the rise in incidence of INH-resistant. 54 However, new data indicates that more than half of patients with INH-monoresistant 55 TB may require a treatment course lasting more than 6 months [5]. Additionally, 56 numerous reports have mentioned significantly varied treatment plans 57 for INH 58 monoresistant TB [6] Mutations in katG or InhA regulatory genes are major genes 59 responsible for INH resistance. Catalase peroxidase, an enzyme that changes INH into its physiologically active form, is encoded by the katG gene. INH was ineffective for 60 treating Mycobacterium tuberculosis with this mutation profile because 61 katG mutations, particularly those at codon 315, provide high levels of INH resistance. The 62 63 principal target of active INH, nicotin-amide adenine dinucleotide dependent enoylacyl carrier protein reductase, as well as ethionamide (ETH) and prothionamide, are 64

all encoded by the InhA regulatory region (PTH) [8]. High doses of INH may be effective against *M. tuberculosis* with InhA mutations result in low-level resistance to the medication [9]. The critical concentrations of INH resistance were categorized as low and high dose with cut off values <0.2 3g/ml and >1 g/ml respectively. Low and high concentration INH resistance can be viewed of as two separate entities because different genetic changes are assumed to be the cause of each [10].

71

Line probe assay (LPA) was developed in response to the MDR-TB crisis in 72 the world and to identify drug resistance in TB patients. Through the National 73 74 tuberculosis elimination program, LPA is a quick method based on polymerase chain reaction (PCR) that is used to identify *Mycobacterium tuberculosis* complex as well 75 76 as drug sensitivity to rifampicin (RPM), isoniazid (INH) and other first line drugs. 77 LPA only examines sputum samples that have an AFB smear positive result [11]. Comparing MDR-TB treatment to non-MDR-TB treatment, unsatisfactory outcomes 78 79 were more connected with MDR-TB treatment [12]. WHO has established a brief treatment regimen for MDR-TB patients in an effort to overcome some of these 80 issues [13]. Numerous studies have been conducted in different nations to identify 81 82 the factors that affect MDR-TB treatment outcomes in both the general population and particular target populations, including adults, children, with comorbidities and 83 those who have co-infected with HIV. These investigations have revealed that there 84 85 are significant regional differences in the predictors of treatment outcome. Body Mass Index (BMI) >18.5kg/m2, use of more than four effective medications, a negative 86 baseline sputum smear, and experiencing a surgical resection are some of the 87 88 variables that were discovered to be related with favourable treatment outcomes [14]. Other factors which included the use of linezolid [15] or fluoroquinolones, 89 customized treatment,[16] getting any help from the TB program, having more 90

91 understanding about the disease, and having more faith and support from nurses and Physicians [9]. Other factors were co-infection with HIV, a positive smear at the 92 beginning of therapy, a history of TB treatment, smoking, pre-XDRTB, age >44 93 years, Ofloxacin resistance, male sex, low body weight at diagnosis (40 kg), poor 94 treatment adherence, smear positive at the second month of treatment, the use of 95 conventional medicine, and treatment interruptions longer than 14 days [17-19]. 96 97 Contradictory results have been found for some of the above-mentioned criteria in trials with unsatisfactory treatment outcomes, though [20] furthermore, there are still 98 99 gaps in the literature regarding the differences between patients with low- and highconcentration monoresistant TB in terms of baseline traits, therapeutic regimen, side 100 events, and outcomes [9]. In the present investigation, it is proposed a) to study the 101 102 clinical profile of patients registered for Drug-Resistant Tuberculosis treatment 103 within Puducherry tuberculosis unit by review of treatment registry. (b). To study the Isoniazid drug resistance pattern and the pattern of resistance mutation in these 104 105 patients by review of Intermediate Reference laboratory (IRL) registry. ©. To assess the treatment outcomes of the INH monoresistant cases as recorded in the DR-TB 106 treatment registry. (d). To correlate the clinical and microbiological profiles with 107 treatment outcomes among patients with Isoniazid monoresistant tuberculosis within 108 109 the Puducherry tuberculosis unit.

- 110
- 111

112

113 Study design & Population

Materials and methods

It is a retrospective record-based study of 100 patients. Patients who had been enrolled in IRL and DRTB registry to have Isoniazid monoresistant pulmonary tuberculosis in Intermediate Reference laboratory, Puducherry. Study involves single group of patients who were diagnosed with Isoniazid monoresistant tuberculosis.

118 Eligibility criteria

| 119 | Inclusion criteria : All the patients who were registered in Intermediate reference |
|-----|---|
| 120 | laboratory and Drug resistant tuberculosis registry as Isoniazid monoresistant |
| 121 | tuberculosis. Patients who had been registered to have mutations in katG gene and |
| 122 | inhA gene. |
| 123 | Exclusion criteria : Patients who had been already diagnosed to have Poly Drug- |
| 124 | Resistant Tuberculosis, Multi-Drug Resistant Tuberculosis, and Extensive Drug |
| 125 | Resistant Tuberculosis. Patient records with incomplete information for the study |
| 126 | Sample Size . All Isoniazid monoresistant patients with above-mentioned inclusion |
| 127 | criteria enrolled in Intermediate reference lab (IRL) from 2014-2020. |
| 128 | Minimum sample size is calculated to be 97 using the below mentioned formula. |
| 129 | $n = (Za)^2[p^*q]$ |
| 130 | |
| 131 | $d^{2}za = 1.96$ |

- 132 Estimated proportion (p)=0.5, q=1-p 1-0.5 = 0.5
- 133 Estimated error (d)=10% (0.1)

134 Sample size (n) =97

135 Study Tools

To assess phenotype and genotype characteristics of patients diagnosed with Isoniazid monoresistant tuberculosis, treatment regimens, treatment failure with the standard regimen and further how many were labelled from Isoniazid monoresistant tuberculosis to poly resistant tuberculosis, multidrug resistance and extensive drug resistant tuberculosis.

- 141
- 142

143 Method of Data Collection

Patients diagnosed with Isoniazid mono-resistant tuberculosis were identified by the collection of data from Intermediate reference laboratory and drug resistant tuberculosis registry, Puducherry. Baseline characteristics/parameters to be included are as follows:

148 · Sex

- 149 · Age
- 150 · Comorbidities
- 151 · Smear positive Status
- 152 · Genes associated with the resistance

153 • Type of resistance – low and high dose Isoniazid resistance.

154 · History of treatment- new and previously treated. Previously treated case can be

relapse (recurrent), failure or default (treatment after default).

156 · Radiographic Findings – Cavitary lesion, Bilateral lesion, Extensive lesion.

157 Treatment success and failure in each of the above Characteristics/Parameters.

158 Data will be entered on Microsoft Excel sheets, checked for accuracy and

159 completeness, and statistically analyzed to evaluate the significance of each risk factor

160 in the development of Isoniazid monoresistant pulmonary tuberculosis.

161 Data Processing and Statistical Analysis

The data was entered with an excel sheet. Data was exported to Medcalc version 163 19.2.6 [21] for further processing. All categorical variables were expressed as 164 percentages and he continuous variables were expressed as mean \pm standard 165 deviation. The statistical significance of mean differences was compared in two 166 groups using a independent t test and categorical variables were analysed using chi 167 square test. All values were considered significant if the *p*-value was < 0.05.

168 **Ethical Consideration**

This research was strictly fulfilling the ethical guidelines as outlined in the declaration of Helsinki, participants signed a consent form, and were assured that their participation was completely voluntary and could be terminated at any time without compromising their medical care. The study protocol was approved by the Mahatma Gandhi Medical College & Research Institute (MGMCRI) Review board.

174

175 **RESULTS**

176

178

177 Demographic and Clinical Characteristics of Patients

A total of 101 patients diagnosed with Isoniazid mono-resistant tuberculosis were identified by the collection of data from the Intermediate reference laboratory and drug resistance tuberculosis registry, Puducherry from 2014-2020 was included in the study. The baseline demographics and clinical characteristics of these patients are listed in Table 1.

184 Age. The study participants mean age was 44.6±15.3 years and ranged from 14 to 87

185 years. The predominant age group was between 40 to 50 years (Fig.1A.a).

186 **Gender**. The predominant gender was male (74%) and followed by the female (26%)

187 observed in the study (Fig.1A b)

188 **Height**. The average height of the study participants was 159.5±7.22 cm and ranged

- 189 from 140 to 174 cm (Fig1A c)
- 190 Weight .The weight of the study population was ranged from 17 to 75 kg with
- average of 48.6±11.5 kg. It showed that majority of the participants were lean body
 weight (Fig.1A d).
- 193 Body mass index (BMI). The average BMI was 18.87±4.51 kg/m2 which showed a
- normal range. However, around 28 % of patients who had below normal BMI wereobserved in the study (Fig1A e).

| 196 | Blood glucose. The blood glucose levels (Fig.1A f) were determined and found that |
|------------|--|
| 197 | the fasting blood glucose levels were higher (177.93±82.50 mg/dl) than random blood |
| 198 | glucose levels (159.27±90.04 mg/dl) |
| 199 | Marital status. In the present study, the majority of the study population was married |
| 200 | (93%) followed by 4% and 3 % of patients who were single and unmarried |
| 201 | respectively (Fig1B a) |
| 202 | Occupation . The predominant study population belongs to coolie (88%) followed by |
| 203 | students (6%) and house-wife (4%). The remaining doctor and salesman were 1% |
| 204 | each (Fig1B b) |
| 205 | Addictions. Smoking was found to be associated in 45% of the patients. Alcoholism |
| 206 | was found in 50 % patients. No addictions was found in 15% patients. (Fig1B c) |
| 207 208 | Co-morbidities. Diabetes mellitus was the only co-morbidity observed in this study |
| 209 | which was 33.67%, systemic hypertension 20.97%, coronary artery disease 6% and |
| 210 | others 4% of the study population did not have any co-morbidities (Fig.1B d) |
| 211 | TB Site. In the study population, the majority of the patients had pulmonary |
| 212 | tuberculosis (98.01%) and 1.98% of the population had extrapulmonary tuberculosis |
| 213 | (Fig.1B e) |
| 214 215 | Clinical Characteristics of the study population |
| 216 | History of anti-tuberculosis treatment . The history of previous ATT was observed |
| 217 | in 43 patients (42.6%). Among 43 patients, sputum positive at diagnosis and |
| 218 | retreatment was found in 31 patients (72.1%). Besides, 58 patients (57.4%) did not |
| 219 | have any previous history of ATT. |

220 Gene responsible. The gene responsible for INH monoresistant TB were KAT G

221 (67.3%) and INH A (32.7%) of patients (Fig.2 a)

222 Mutation Pattern. The katG Mut1 was a prime mutation observed in the present study population (58.41%). Besides, inhA Mut1 was found in 23.76%, inhA Mut1 223 present &WT1absent in 7.9%, katG Mut1 present & WT1 absent in 6.9%, and other 224 mutations were observed in 2.97% (Fig.2 b) 225 Comparison of clinico-microbiological profile in INH low and high concentration 226 resistance 227 The clinico-microbiological parameters were compared with the low and high 228 levels of INH mono-resistance listed in table 2. The mean age of the patients with 229 230 low- and high-concentration mono-resistant TB were 44.54±14.68 and 44.59±15.80 years respectively. It showed statistically not significant (P=0.9881) (Fig.2 c). Male 231 gender was 68.6% and 75.75% in low- and high-concentration mono resistant TB 232 233 respectively. The male gender was significantly higher in high concentration monoresistant TB (p=0.0025) (Fig.15). Besides, the female gender was not significantly 234 differed between the two groups of patients (p=0.3359). The average height of low 235 and high concentration mono-resistant TB was 159.20±8.51and 159.68±6.53 236 respectively. Between both groups, the mean height was almost the same and was not 237 statistically significant (p=0.7772) (Fig.2 d) 238

The mean weight of low and high-concentration mono-resistant TB did not show any statistically significant difference (p=0.4142) (Fig.2 e). The mean body mass index (BMI) in low concentration mono-resistant TB was 18.82 ± 5.42 and in high concentration mono-resistant TB was 18.9 ± 4.02 . The BMI in both groups has shown almost similar which was statistically no significant difference (p=0.9407) (Fig.3 a).

The previous history of ATT was higher in high concentration resistance than in low concentration which was statistically significant (p=0.0474) (Fig.3 b). Smoking

and alcoholism as addiction history was predominant and significantly higher in high concentrations than in low concentrations (p=0.0373) (Fig.3 c). The occurrence of TB in the pulmonary region was predominant and significantly higher in high concentrations than in low concentrations (p=0.0002) (Fig.3 d).

251

252 Pattern of Gene mutation

The most common mutation in INH-resistant strains was in the katG gene 253 254 (64.35%) followed by *inh*A gene (34.65%). In 1 (1%) patient, both *inh*A and *kat*G gene mutations were observed (Table 3 & Fig.4). Comparing the pattern of gene 255 mutations in INH monoresistant strains revealed that of 35 isolates with only *inhA* 256 gene mutation, WT1 pattern was absent and MUT1 present in 8 (22.9%) strains, WT2 257 pattern was absent and MUT1 present in 3 (8.6%), while MUT1 pattern was present 258 in 24 (68.6 %) strains. *Kat*G gene mutation patterns were observed in 66 isolates with 259 260 different sequences. WT1 was absent and MUT1 was present in 6 (9.1%), inhAWT2 was absent and inhA MUT1 was present in 1 (1.5 %), MUT1 was seen in 58 (87.9%) 261 patients (Table 4). 262

263 **Treatment outcome**

Out of 101 INH monoresistant tuberculosis patients, 35 had low-dose concentration resistance (inhA), of which 28 patients were cured. 66 patients had high dose resistance (katG), of which 49 patients were cured. Cure rate was high in *INH high concentration resistance* patients which were statistically significant (p=0.0167) (Fig.5)

269 Treatment impact on weight

The treatment impact on patients' weight was determined and found that weight gain was a major outcome in both low and high concentrations (Table 6). However, the weight gain was not statistically significant (p=0.0622) (Fig.6 A). Similarly, the

weight loss was also statistically not significant (p=0.7247) (Fig.6 B). Besides, there 273 were no changes in weight after treatment was observed in some patients but it was 274 275 not significantly differed.

DISCUSSION 276

277

As a result of its effective early bactericidal activity against rapidly 278 proliferating cells, isoniazid is a crucial first-line anti-TB medication [22]. Isoniazid 279 280 helps to prevent the selection and formation of a drug-resistant TB population when used in combination with other anti-TB medications. But among all first-line 281 medications, isoniazid resistance is the most prevalent, with an estimated frequency of 282 13% globally, including new and retreatment cases [23]. It is still unknown what the 283 best treatment plan is for isoniazid mono-resistant TB. According to several recent 284 studies, [24,25] individuals with isoniazid mono-resistant TB fared worse than those 285 with drug-susceptible TB, despite studies from the 1970s and 1980s reporting a low 286 rate of treatment failure for those receiving four or five medications over a six month 287 period. 288

According to the results of the current investigation, Diabetes mellitus affected 289 33% of the patients. Receduly, West Bengal study [26] found that 43% of TB 290 291 patients also had diabetes. A study conducted in Indonesia, Peru, South Africa and Romania with a high TB burden found that 12.5% of TB patients had diabetes [27]. 292 The WHO strategy of routine bidirectional symptom-based TB screening in known 293 DM patients in high TB burden countries has been endorsed by Alisjahbana et al.[28]. 294 295 In our current study Diabetes patients having 54 history of previous tuberculosis and 296 ATT intake are having high dose isoniazid monoresistance (katG). The people who had arrived for the presumed TB test were overwhelmingly male. Male patients made 297 up 74% of those with MTB positivity. Our results are in line with those of recent 298

299 studies in India that found that 76%, 75%, 70.5%, 71%, and 72% of TB patients were males, as reported [29-32]. According to the WHO study from 2021, adult males, 300 who made up 56% of all TB cases in 2019, have the highest prevalence of the disease 301 302 [6]. More than one gene or gene complex, including the katG, inhA, and kasA genes as well as the intergenic region of the oxyR ahpC complex, may be altered in the 303 genetic foundation of INH resistance [33]. Two genes, katG and inhA, have probes 304 305 that can be used to identify INH resistance in Genotype MTBDR +. According to Van Rie et al. [34] the katG mutation was less common (37.6%). Numerous studies have 306 307 demonstrated a correlation between high and low levels of INH resistance and the codon 315 of the katG gene (50%-90%) and regulatory region of the inhA gene 308 (20%-35%), respectively[35]. In our study we found that the katG gene (67% of 309 310 patients had this mutation), followed by the inhA gene (33% of patients). Yao et al. 311 (2010) obtained results that were almost identical. A 50 INH monoresistant patients were examined, and it was found that 41 (82%) had KatG mutations and 9 (18%) had 312 313 inhA mutations [36]. In addition, according to Huyen et al., 28.2% and 75.3%, respectively, of the population, contained mutations in the inhA promoter region [37]. 314 Similar findings were made by Kigozi et al. (2018) who found that 6% of samples 315 had inhA mutations and 80% had katG mutations [38]. 316

In addition, Tavakkoli and Nazemi (2018) reported that inhA genes and katG genes, respectively, were in charge of INH resistance in 17.24% and 82.76% of the strains [39]. Niehaus et al. discovered that 33.1% of 924 isolates, or 30.3% of those with MDR TB, 47.2% of those with pre-XDR-TB, and 82.8% of those with XDR-TB, carried an inhA mutation with or without a katG mutation [40]. Alagappan et al. (2018) looked into the promoter region of the inhA gene and codon katG for INH resistance mutations in M. tuberculosis. Of the 15,438 INH resistant bacteria, 1,821

324 (11.8%) showed detectable mutations, with 71.0% occurring in katG315 and 29.0% in the inhA promoter region[41]. Isakova et al. (2018) found that the katG gene was 325 mutated in 91.2% of strains, the inhA gene was mutated in 7% of specimens, and the 326 ahp C gene was mutated in 2 more specimens (1.8% of the total) [42]. Jagielski et al. 327 (2015) also noted that katG mutations were present in 85.2% of MDR patients. 328 Approximately 3.7% of the 54 patients had only one inhA mutation, and the 329 330 remaining patients, or 11.1%, had both mutations [43]. A comparative outcomes.are shown in Table 7. 331

332 Clinicians should be aware of mutations in the katG or inhA promoter region.[44] and high level of resistance to INH is indicated by the existence of 333 mutations in katG alone or in conjunction with inhA. For these patients, adding even 334 335 high doses of INH is unlikely to improve the efficacy of a regimen. On the other hand, a mutation restricted to inhA is typically associated with a low level of INH resistance, 336 and these people are likely to benefit from large doses of INH (10–15 mg/kg/day) 337 [45]. Results of our study showed mean age of incidence with low- and high 338 concentration mono-resistant TB were 44.54±14.68 and 44.59±15.80 years 339 respectively. It showed statistically not significant (p=0.9881). Besides, the male 340 gender was 68.6% and 75.75% in low-and high-concentration mono-resistant TB 341 342 respectively. The average height of the study participants was 159.5±7.22 cm and 343 ranged from 140 to 174 cm. The weight of the study population was ranged from 17 to 75 kg with average of 48.6 ± 11.5 kg. It showed that majority of the patients in the 344 study had low BMI. The predominant study population belongs to coolie (88%) 345 346 followed by students (6%) and housewife (4%). The remaining doctor and salesman were 1% each. Diabetes mellitus was the most common co-morbidity observed in this 347 study which was 33% in the population. Smoking and alcohol association was 348

349 associated with patients diagnosed with high dose INH monoresistant tuberculosis (53.03%) of which significant of the patients were associated with retreatment 350 (68.57%). In the study population, most of the patients had pulmonary tuberculosis 351 352 (98.01%) and 1.98% of the population had extrapulmonary tuberculosis (pleural effusion). The history of previous ATT was observed in 43 patients (42.6%). Among 353 43 patients, sputum positive at diagnosis and retreatment was found in 31 patients 354 (72.1%). Besides, 58 patients (57.4%) did not have any previous history of ATT. INH 355 high dose monoresistance was seen in 66 patients and low dose mono resistance was 356 357 58 seen in 35 patients. The predominant gene responsible for TB was katG (64.3%) and inhA gene was observed in 34.65% of patients. The katG Mut1 was a prime 358 mutation observed in the present study population (58.41%). Besides, inhA Mut1 was 359 360 found in 23.76%, inhA Mut1 present &WT1 absent in 7.9%, katG Mut1 present & 361 WT1 absent in 6.9%, and other mutations were observed in 2.97%. Treatment outcomes showed 77 patients were cured (74.75%), 17 patients were lost to follow up 362 363 (16.5%), 3 patients died during the course of treatment (2.91%), treatment failure was seen in 2 patients (1.94%), treatment regimen changed in 1 patient (0.97%). Study 364 showed positive association with males (74%), occupation as coolie (88%), diabetes 365 as comorbidity (33%), pulmonary tuberculosis as the TB site (98.01%), history of 366 367 previous ATT intake in 43 patients (42.6%), katG mutation (67.3%), katG Mut 1 was 368 the prime mutation (58.4%). Study also showed that male patients with diabetes has comorbidity, with history of ATT intake along with sputum positive at diagnosis and 369 retreatment (72.1%) were associated with INH high dose monoresistance (katG), 370 371 having katG Mut 1 as prime mutation. The importance of treating physicians being aware of these gene alterations as well as the usefulness of laboratories reporting 372 these mutations cannot be overstated. 373

374 CONCLUSION

375

Patients with both smoking and alcohol addictions were with INH high dose 376 monoresistance (katG), of which katG Mut 1 prime mutation was predominant 377 (53.03%). A 32 patients with history of previous tuberculosis were diagnosed to have 378 379 recurrent tuberculosis with high dose INH monoresistance out of which 27 had diabetes, smoking and alcohol association (84.3%). Current study showed that there 380 is high prevalence of INH monoresistance in patients with previous H/O ATT intake, 381 alcohol, smoking and diabetes. Results of the study showed that there is a 382 significant association between males, diabetes, smoking and alcohol addictions were 383 384 associated with high risk of developing high dose INH monoresistance (katG)In Pondicherry, due to effective screening, implementation of NTEP program and there 385 has been a rise in incidence of INH monoresistance tuberculosis in past few years 386 387 raising a concern for increase in risk of treatment failure and multi drug resistant Present study conclude that high prevalence of addictions, prevailing tuberculosis. 388 low socioeconomic class had influence in treatment outcomes, incidence of recurrent 389 cases and high risk for development of INH monoresistance 390 tuberculosis in Puducherry. Patients who are microbiologically confirmed pulmonary tuberculosis 391 392 and diabetes with rifampicin sensitive status needs to be checked for LPA for isoniazid sensitivity status to prevent treatment failure and relapse. It is crucial to 393 understand the gene pattern in each of these patients since these mutations are closely 394 395 associated to high or low-degree resistance to INH.

396 397

398

399

400

| 403 404 405 | Acknowledgments |
|-------------------|---|
| 403 | We would like to acknowledge Dr. Muthuraj R, chief microbiologist, Intermediate |
| 407 | reference laboratory, Puducherry, for his support in providing laboratory data and Dr |
| 408 | Ezhumali for his statistical assistance. |
| 409 410 411 | Author Contributions |
| 412 | Conceptualization: Pajanivel R, Venkata Prasanna M |
| 413 | Data curation: Venkata Prasanna M |
| 414 | Formal analysis: Pajanivel R, Venkata Prasanna M, Muthuraj R, Vimal Raj R |
| 415 | Methodology: Pajanivel R, Venkata Prasanna M, Muthuraj R |
| 416 | Software: Venkata Prasanna M |
| 417 | Supervision: Pajanivel R, Muthuraj R, Govindarajan S, Vimal Raj R |
| 418 | Visualization: Venkata Prasanna M, Pajanivel R, Muthuraj R, .Govindarajan S, Vimal |
| 419 | Raj R |
| 420 | Writing –Venkata Prasanna M, Pajanivel R |
| 421 | Original draft: Venkata Prasanna M, Pajanivel R, Muthuraj R, Vimal Raj R |
| 422 | Writing – review & editing: Venkata Prasanna M, Pajanivel R, Muthuraj R, |
| 423 | Govindarajan S, Vimal Raj R |
| 424 | |
| 425 426 | |
| 427 | |
| 428 | |
| 429 | |
| 430 | |
| 432 | |
| 433 | |
| 434 | |
| 435 | |
| 436 | |
| 40- | |

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285245; this version posted February 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license . 439 References 440 441 redirect/9789240013131 442 443 444 tuberculosis-programme/tb-reports 445 446

- 1. Global tuberculosis report Oct.27, 2022, https://www.who.int/publications-detail-2. Global Tuberculosis Report s July 14,2022, https://www.who.int/teams/global-3 Report ITR 14, 447 713587265 workshop.pdf Jul 448 2022 :https://tbcindia.gov.in/WriteReadData/1892s/713587265Report ITR%20works 449 ho p.pdf 450 451 4. Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic 452 resistance in Mycobacterium tuberculosis. Int J Infect Dis. 2015;32:94–100. 453 454 5. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-455 monoresistant tuberculosis. Clin Infect Dis. 2009; 48(2):179-85. 456 457 6. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among 458 459 tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis. 2012;16(6):812-6. 460 461 7. Almeida Da Silva PEA, Palomino JC. Molecular basis and mechanisms of drug 462 resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob 463 Chemother. 2011; 66(7):1417-30. 464 465 8. Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, et al. Clinical 466 467 Characteristics and Treatment Outcomes of Patients with Low- and High Concentration Isoniazid-Monoresistant Tuberculosis. PLOS ONE 468 2014: :9(1):e 86316.. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086316 469 470 471 9..Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for 472 473 drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(8):1099–104. 474 10. Desikan P, Panwalkar N, Mirza SB, Chaturvedi A, Ansari K, Varathe R, et al. 475 Line probe assay for detection of *Mycobacterium tuberculosis* complex: An 476 experience from Central India. Indian J Med Res. 2017 477 ;145(1):70-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460577/ 478 479 11. Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Ba Z, Naing NN. Treatment 480 481 Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia. Malays J Med 482 Sci.
- 2016;23(4):17-25. 483

484 12. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment 485 outcomes for HIV and MDR-TB co-infected adults and children: systematic review 486 and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969-78. 487 488 489 13. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively 490 drug-resistant tuberculosis. Clin Infect Dis. 2008;47(4):496–502. 491 492 493 14. Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment 494 outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(5):525-30. 495 496 497 15. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta 498 analysis of published studies. Infectious Diseases of Poverty. 2017;6(1):7. 499 500 https://doi.org/10.1186/s40249-016-0214-x 501 502 16 Tupasi TE, Garfin AMCG, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, 503 et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis. 504 505 2016;22(3):491-502. 506 17. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment 507 508 Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi Investigation. 509 Center **PLOS** ONE 2013;8(12):e82943. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082943 510 511 18. Predictors of poor treatment outcome in multi- and extensively drug-resistant 512 pulmonary Respiratory Society 2022. 513 TB European https://erj.ersjournals.com/content/33/5/1085 514 515 516 19. Periasamy A. Predictors of Outcome in Drug Resistant Tuberculosis Patients. J 517 Pulm Respir Med https://www.omicsonline.org/open-518 2017;07(01). access/predictors-of-outcome-in-drug resistant-tuberculosis-patients-2161-105X-519 1000391.php?aid=86111 520 521 20. Elliott E, Draper HR, Baitsiwe P, Claassens MM. Factors affecting treatment 522 outcomes in drug-resistant tuberculosis cases in the Northern Cape, South Africa. 523 2014;4(3):201-3. 524 Public Health Action https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533815/ 525 526 21. MedCalc Statistical Software version 19.2.6 (MedCalc Software bv, Ostend, 527 528 Belgium; https://www.medcalc.org; 2020)" 529 530 22. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, 531 532 al. American Thoracic Society/Centers for Disease Control and et Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J 533

Respir Crit Care Med. 2003 ;167(4):603-62. 534

| 35 36 37 38 | 23. Anti-tuberculosis drug resistance in the world : fourth global report 2022 Aug 28]. https://www.who.int/publications-detail redirect/9789241563611 |
|----------------------------|---|
| 39 40 41 42 43 | 24 Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009 :6(9):e1000150 |
| 43 44 45 46 47 | 25. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005 ;5(1):14. <u>https://doi.org/10.1186/1471-2458-5-14</u> |
| 48 49 50 51 52 | 26. Kundu S, Sikder R, Dey R, Majumdar K, Joardar G. Study of socio demographic and treatment profile and other epidemiological correlates of clients attending revised national tuberculosis control programme clinic in a tertiary hospital of West Bengal, India International Journal Of Community Madiaina And Public Health 2020 |
| 53 54 55 56 57 | 1;7:742–7. 27. Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, et al. Diabetes Mellitus Among Pulmonary Tuberculosis Patients |
| 58 59 60 61 62 | 28. Alisjahbana B, McAllister SM, Ugarte-Gil C, Panduru NM, Ronacher K, Koesoemadinata RC, et al. Screening diabetes mellitus patients for pulmonary |
| 63 64 65 66 | tuberculosis: a multisite study in Indonesia, Peru, Romania and South Africa. Trans R Soc Trop Med Hyg. 2021;115(6):634–43. 29. Mathur RB, Shukla US, Bindal HK. Role of cartridge-based nucleic acid |
| 67 68 69 70 | amplification test to diagnose tuberculosis at tertiary care teaching hospital in Rajasthan, India. International Journal of Research in Medical Sciences . 2019;7(11):4243–8. <u>https://www.msjonline.org/index.php/ijrms/article/view/7340</u> |
| 71 72 73 74 75 | 30. Jethani S, Kakkar R, Semwal J, Rawat J. Socio- Demographic Profile of Tuberculosis Patient: A Hospital Based Study at Dehradun. National Journal of Community Medicine 2014;5(01):6–9. https://www.njcmindia.com/index.php/file/article/view/1303 |
| 76 77 78 79 | 31. M S, Y SC, M R, D IG. Patient and health system delays in diagnosis and treatment of tuberculosis patients in an urban tuberculosis unit of south India. International Journal Of Community Medicine And Public Health. 2017;3(4):796–804. <u>https://www.ijcmph.com/index.php/ijcmph/article/view/799</u> |
| 31 32 33 | 32 S US, Kumar AMV, Venkateshmurthy NS, Nair D, Kingsbury R, R P, et al Implementation of the new integrated algorithm for diagnosis of drug-resistant tuberculosis in Karnataka State, India: How well are we doing? PLOS ONE |

| 584 585 | 2021;16(1):e0244785. <u>https://journals.plos.org/plosone/article?id=10.1371/journal.pon</u> <u>e.0244785</u> |
|---|--|
| 586 587 588 589 590 | 33. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2(3):164–8. |
| 591 592 593 594 | 34. Van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD, Richardson M, et al. Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of Mycobacterium tuberculosis in a High-Incidence Community. J Clin Microbiol.2001;39(2):636–41 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC87790/</u> |
| 595 596 597 598 599 | 35. Miotto P, Piana F, Cirillo DM, Migliori GB. Genotype MTBDRplus: a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis. J Clin Microbiol 2008;46(1):393–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2224251/ |
| 600 601 602 603 604 605 | 36. Yao C, Zhu T, Li Y, Zhang L, Zhang B, Huang J, et al. Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray. Clin Microbiol Infect. 2010; 16 (11):1639–43. |
| 606 607 608 609 610 | 37. Huyen MNT, Cobelens FGJ, Buu TN, Lan NTN, Dung NH, Kremer K, et al. Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes. Antimicrob Agents Chemother . 2013;57(8):3620–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719713/ |
| 611 612 613 614 615 616 617 | 38. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, et al Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLOS ONE . 2018;13(5):e0198091. <u>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198091</u> |
| 618 619 620 621 622 623 624 | 39 Tavakkoli Z, Nazemi A. Genotyping of Related Mutations to Drug Resistance in Isoniazid and Rifampin by Screening of katG, inhA and rpoB Genes in Mycobacterium tuberculosis by High Resolution Melting Method. Mycobact Dis 2018 ;08(03). Available from: <u>https://www.omicsonline.org/open-access/genotyping-of-related-mutations-to</u> drug-resistance-in-isoniazid-andrifampin-by-screening-of-katg-inha-and-rpob genes-in-mycobacter-2161-1068-1000265-103777.html |
| 625 626 627 628 629 630 | 40. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JCM. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. PLOS ONE 2015;10(9):e0135003. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135003 |
| 631 632 633 | 41. Alagappan C, Sunil Shivekar S, Brammacharry U, Cuppusamy Kapalamurthy VR, Sakkaravarthy A, Subashkumar R, et al. Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re- |

treated smear-positive pulmonary tuberculosis patients: A meta-analysis. J Glob 634 Antimicrob Resist. 2018;14:253-9. 635 636 42.. Isakova J, Sovkhozova N, Vinnikov D, Goncharova Z, Talaibekova E, Aldasheva 637 N, et al. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-638 resistant Mycobacterium tuberculosis in Kyrgyz Republic. BMC Microbiol. 639 2018;18(1):22. 640 641 43. Jagielski T, Bakuła Z, Roeske K, Kamiński M, Napiórkowska A, Augustynowicz-642 Kopeć E, et al. Mutation profiling for detection of isoniazid 92resistance in 643 Mycobacterium tuberculosis clinical isolates. J Antimicrob 644 Chemother. 201;70(12):3214-21. 645 646 44. Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary 647 tuberculosis in India: systematic review and meta-analysis. BMC Public Health 648 2017;17(1):817. https://doi.org/10.1186/s12889-017-4779-5 649 650 45. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the 651 guidelines WHO treatment for drug-resistant tuberculosis.. 652 https://www.who.int/publications/i/item/9789241550079 9 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285245; this version posted February 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





- occuring site





710 Figure 2 c Comparison of Age between Low & high-concentration mono-resistant 711

709

712

716



713 Figure 2 e Comparison of height between low & high-concentration monoresistant TB 714 715





Figure 2.d Comparison of gender between low & high-concentration mono resistant TB



Figure 2 f Comparison of weight between Low^ & high-concentration mono resistant TB

717 Figure 2 Comparision of age, gender, height and weight between low & high 718 719 concentration monoresistant TB





Fig.3 a. Comparison of BMI between low &high-concentration mono-resistant





726

720

727 Figure 3. Comparison of BMI, ATT, Adiction and pulmanary TB

- 728
- 729
- 730









Figure 4 B Treatment outcome between two groups

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285245; this version posted February 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.





Table 1: Baseline characteristics of the study population

| Characteristics | Mean± SD N (%) | |
|-------------------------|-------------------|--|
| Age in years | 44.6±15.3 | |
| Gender (M:F) | 75:26 | |
| Height in cm | 159.5±7.22 | |
| Weight in kg | 48.6±11.5 | |
| BMI kg/m ² | 18.87±4.51 | |
| FBS | 177.93±82.50 | |
| RBS | 159.27±90.04 | |
| Marital Status | 2 | |
| Married | 94 (93.06%) | |
| Unmarried | 07 (6.94%) | |
| Comorbidities | | |
| DM | 33 (32.67%) | |
| Systemic Hypertension | 21 (20.79%) | |
| Coronary artery disease | 06 (5.94%) | |
| TB Region | | |
| Pulmonary | 100 (98.01%) | |
| Extrapulmonary | 01 (1.98%) | |

| Parameters | INH low concentration resistance N=35 | INH high concentration resistance N=66 | p Value | |
|---------------------------|---|--|---------|--|
| Age | 44.54±14.68 | 44.59±15.80 | 0.9881 | |
| Male | 24 (68.6%) | 50 (75.75 %) | 0.0025 | |
| Female | 11 (31.4 %) | 16 (24.24%) | 0.3359 | |
| Height in cm | 159.20±8.51 | 159.68±6.53 | 0.7772 | |
| Weight in kg | 49.93±12.04 | 47.92±11.25 | 0.4142 | |
| BMI kg/m ² | 18.82±5.42 | 18.9±4.02 | 0.9407 | |
| H/O ATT | 15 | 28 | 0.0474 | |
| Alcoholism | 6 | 18 | 0.0484 | |
| Smoking | 4 | 10 | 0.0442 | |
| Smoking and alcohol | 14 | 35 | 0.0213 | |
| Pulmonary tuberculosis | 30 | 66 | 0.0002 | |

796 Table 2: Demographic and clinical characteristics of the patients

Gene N % 34.65 inhA katG 64.35 Both 811

Table 3: Pattern of gene mutations in INH-resistant TB strains

Table 4: Analysis of patterns of gene mutations at various loci of InhA and katG in Isoniazid Mono-resistant Tuberculosis Patients

| Gene | INH low concentration resistance N=35 | | | INH high concentration resistance N=66 | | | | |
|------|--|------------|-------------|---|--------|------------|-------------|-------------|
| | Locus | | | | | | | |
| | WT1(-) | WT2 (-) | MUT1 (+) | MUT2 (+) | WT1(-) | WT2 (-) | MUT1 (+) | MUT2 (+) |
| inhA | 8 | 3 | 35 | - | | 1 | 1 | |
| KatG | (*) | | 2) 10 | - | 6 | 2) | 60 | 2 |

856 Table 5: Treatment outcome between two groups

| Treatment Outcome | INH low concentration resistance N=35 | INH high concentration resistance N=66 | P value |
|------------------------------|--|---|---------|
| Cured | 28 | 49 | 0.0167 |
| Follow up Lost | 06 | 11 | 0.1573 |
| Died | 01 | 02 | 0.5637 |
| Failure | 0 | 02 | 2 |
| Treatment Regimen changed | 0 | 01 | • |

873 Table 6: Impact of Treatment on weight

| Weight Status | INH low concentration resistance N=35 | Mean±SD | INH high concentration resistance N=66 | Mean±SD | p Value |
|------------------|--|-------------------|--|-----------|---------|
| Weight Gain | 19 (54.3%) | (4.10±2.23 kg) | 41(62.12%) | 3.09±1.74 | 0.0622 |
| Weight Lost | 3 (8.6%) | (3±1 kg) | 3(4.54%) | 2.7±1.1 | 0.7247 |
| No change | 7 (20%) | 07.0 | 8 (12.12%) | - | |